Glaukos Corp (GKOS.N): WPS’s LCD Discussion Reinforces Support for iDose

Research evidence excerpt

Glaukos Corp (GKOS.N): WPS’s LCD Discussion Reinforces Support for iDose

Flash |

24 Jun 2026 17:59:43 ET │ 10 pages

Glaukos Corp (GKOS.N)

WPS’s LCD Discussion Reinforces Support for iDose

CITI’S TAKE

Following the proposed LCD for the anterior segment intraocular non-

Buy biodegradable drug-eluting system (iDose TR, link) published on

Price (24 Jun 26 16:00) US$137.76 5/21/2026, WPS hosted its public meeting today to solicit feedback.

Much like Palmetto’s meetings on Monday, the discussion emphasized Target price US$162.00

the importance of preserving physician flexibility, personalized patient Expected share price return 17.6%

treatment plans, and minimization of clinical burdens. Specifically, Expected dividend yield 0.0%

feedback included: 1) the modification of the two ophthalmic topical drops Expected total return 17.6%

requirement to just one; 2) change the “and” modifier in the “history of Market Cap US$8,091M

failed medical management and failed SLT” coverage description to “or”;

3) remove the concomitant procedure limitation; and 4) revisit the central

corneal endothelial cell density requirement. The WPS meeting was

encouraging and there is a clear consensus that the proposed LCD is too Joanne WuenschAC

restrictive and a misrepresentation of real-world practices. We look +1-212-816-9606

forward to additional MAC meetings later this week, including: 1) NGS on joanne.wuensch@citi.com

6/25; and 2) Noridian on 6/25. We rate GKOS Buy. Anthony Occhiogrosso

+1-212-816-7579

The patient’s central corneal endothelial cell density limitation is restrictive. In anthony.occhiogrosso@citi.com

addition to echoing many of what was discussed in the Palmetto meeting (link), the

Jane-Marie LaiWPS discussion dives deeper into the LCD’s limitation #4: “Preimplantation, the